AGC Biologics A/S

Company's own description on virk.dk

Activities and Business ModelAGC Biologics A/S (“AGC” or the “Company”) is a Contract Development Manufacturing Organization (CDMO) that provides high value added process and analytical development, scale-up and production of biological drug substances such as antibodies to the biopharmaceutical industry.The Company has a comprehensive service offering and is capable of taking a product from the early stage to commercial production. The service palette goes from cell line and process development over analytical testing and formulation development to both clinical and commercial manufacturing. All supported by quality services, including regulatory support.The Company is owned by AGC Inc. and is a part of the AGC Group.AGC Biologics Group operates fully integrated process development and manufacturing facilities in Copenhagen, Denmark (AGC Biologics A/S); Seattle, Boulder, and Longmont, USA (AGC Biologics Inc.); Heidelberg, Germany (AGC Biologics GmbH); and Chiba, Japan (AGC Inc.). In addition, the Group has dedicated cell and gene therapy facilities located in Milan, Italy (AGC Biologics S.p.A.). All operations of AGC Biologics A/S are carried out exclusively at its facility in Denmark.2025 was characterized by continued challenging market conditions, which resulted in financial performance below prior year expectations. Despite this, AGC maintained operational stability and continued to progress on key strategic priorities. The Company remained focused on strengthening its infrastructure and organizational capabilities to support future growth. Investments in production capacity and workforce development continued, ensuring readiness for increasing business intake.AGC is well-positioned for the future, supported by its expanded facilities and ongoing commitment to operational excellence and customer delivery.In 2025, the new mammalian production facility next to the existing production site was fully operational, with line A now in production. The DKK 1.5 billion investment significantly expands the company’s mammalian production capacity and supports future growth.Further, in 2025 AGC continued to emphasize safety, compliance, and quality, while maintaining a strong focus on customer satisfaction, expanding market reach, and ensuring timely and reliable delivery supported by high-quality standards and advanced technology.Since AGC was started in 2001, the Company’s growth is a result of significant repeat business from customers, combined with an enlarged customer base and an important increase in the average customer contract size. This positive development has to a very large extent been possible due to the highly skilled and dedicated employees at AGC.As the number of customers and projects increases and contracts become larger, higher demands are imposed on the Company's ability to manage a complex and increasingly differentiated production portfolio. To ensure flexibility, high quality, robustness and efficient production AGC continued also in 2025 to strengthen its organization and production processes.“The statement of compliance with the Danish Financial Statements Act, Section 99 (a) and Section 99 (d), is disclosed in the Sustainability Statement 2025.(https://www.agcbio.com/hubfs/AGC%20Bio%20CPH%20Sustainability%20Statement%202025%20-%20Final.pdf).